Update on status of FIRB approval
Released
Released
Announcement PDF
ASX Announcement
UPDATE ON STATUS OF FIRB APPROVAL
7 November 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma)
refers to its proposed acquisition by Cosette Pharmaceuticals, Inc. (Cosette) by way of scheme of
arrangement (Scheme).
On the evening of 6 November 2025, Mayne Pharma was notified that the Foreign Investment
Review Board (FIRB) had unilaterally extended the statutory deadline for FIRB approval to
14 November 2025.
As previously announced on 4 November 2025, the Court hearing to approve the Scheme (Second
Court Hearing) has been rescheduled to take place at 8.30am (AEDT) on Tuesday, 18 November
2025.
The Scheme remains subject to FIRB approval, Court approval and other conditions as set out in
the Scheme Booklet (and as outlined in clause 3.1 of the Scheme Implementation Deed). On the
basis that these conditions are satisfied, an updated indicative timetable is set out below. This
timetable remains subject to ASX approval.
Event Expected Date
Second Court Hearing to Approve the Scheme Tuesday, 18 November 2025
at 8:30am AEDT
Effective Date
Mayne Pharma shares will be suspended from trading at the
close of trading on ASX on the Effective Date. If the Scheme
proceeds, thiswill be thelast day that MaynePharma shareswill
trade on ASX
Wednesday, 19 November
2025
Scheme Record Date
For determining entitlements to the Scheme consideration
Friday, 21 November 2025
at 7:00pm AEDT
Scheme Implementation Date
All Scheme shareholders will be sent the Scheme consideration
to which they are entitled on this date
Monday, 1 December 2025
This timetable is indicative only. All dates and times, unless otherwise indicated, refer to the date
and time in Australian Eastern Daylight Savings Time. Any changes to the above timetable will be
announced to ASX and notified on Mayne Pharma’s website at maynepharma.com.
If FIRB approval is received prior to 14 November 2025, Mayne Pharma may ask the Court to bring
forward the date for the Second Court Hearing. Mayne Pharma will keep shareholders updated if
such a request is made.
Mayne Pharma Shareholders do not need to take any action at this time.
- ENDS -
ASX Announcement
Page 2
Authorised for release to the ASX by the Board Chair
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
Share your feedback
Discover